Anti-Human MUC1 Recombinant Antibody (C595) (CAT#: TAB-429MZ)
This product is a humanized antibody capable of binding to the MUC1 mucin antigen comprised of a light chain and a heavy chain. The C595 monoclonal antibody targets the epitope Arg-Pro-Ala-Pro on the MUC1 protein core. It has been used both in vitro and in vivo in the diagnosis of breast and bladder cancer research.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
Figure 1 Dose-tolerance studies for escalating single-dose administration of single or combination treatments for the first 3 weeks in nude mice without tumors.
Dose-tolerance relationship in mice by single MAb C595.
Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).
Figure 2 Dose-tolerance studies for escalating single-dose administration of single or combination treatments for the first 3 weeks in nude mice without tumors.
Dose-tolerance relationship in mice by combination test [MAb C595 (5 mg/kg)+DTX (3–10 mg/kg)].
Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).
Figure 3 Dose-tolerance studies for escalating single-dose administration of single or combination treatments for the first 3 weeks in nude mice without tumors.
Dose-tolerance relationship in mice by combination control [MAb IgG3 control (5 mg/kg)+DTX (3–10 mg/kg)].
Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).
Figure 4 Cumulative ascites volume, tumor weight and CA125 levels at the end of experiments after single MAb C595 and DTX treatment in OVCAR-3 animal model.
Cumulative volumes of ascites collected from each animal from initiation of therapy [MAb C595 (H and L), MAb IgG3, DTX (H and L) are shown. The obvious difference was seen between DTX(H)-treated group and others-treated group (P<0.05).
Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).
Figure 5 Cumulative ascites volume, tumor weight and CA125 levels at the end of experiments after single MAb C595 and DTX treatment in OVCAR-3 animal model.
Tumor weights (mg) at the end of experiments after single MAb C595, MAb IgG3, DTX or vehicle treatments with different doses. The tumor weigh was obviously lower in MAb-treated and DTX-treated groups compared to MAbIgG3-treated and HPMC-treated control groups (P<0.05).
Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).
Figure 6 Cumulative ascites volume, tumor weight and CA125 levels at the end of experiments after single MAb C595 and DTX treatment in OVCAR-3 animal model.
Effect of single MAb C595, MAb IgG3, DTX or vehicle on suppressing the increase in the tumor marker CA125 (CA125 Ku/L) in the ascites fluid (peritoneal wash) at the end of experiments. The level of CA125 was obviously lower in MAb C595 (H)-treated and DTX-treated groups compared to MAbIgG3-treated and HPMC-treated control groups (P<0.05).
Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).
Figure 7 Representative images of histological changes, MUC1 and CD31 expression at the end of experiments after combination and control treatments.
Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).
Figure 8 Representative images of Ki-67, TUNEL, Caspase-3 (Active) and PARP-1 (Cleaved 85) at the end of experiments after combination and control treatments.
Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., ... & Li, Y. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6(9).
Specifications
- Host Species
- Mouse
- Specificity
- Human
- Clone
- C595
- Applications
- ELISA, FuncS, FC, IHC
- Related Disease
- Metastatic bladder cancer, breast cancer
Applications
- Application Notes
- The antibody was validated for ELISA, Functional Assay, Flow Cytometry, Immunohistochemistry. For details, refer to Published Data.
Target
- Alternative Names
- MUC1; mucin 1, cell surface associated; EMA; MCD; PEM; PUM; KL-6; MAM6; MCKD; PEMT; CD227; H23AG; MCKD1; MUC-1; ADMCKD; ADMCKD1; CA 15-3; MUC-1/X; MUC1/ZD; MUC-1/SEC; mucin-1; episialin; DF3 antigen; H23 antigen; cancer antigen 15-3; krebs von den Lungen-6; mucin 1, transmembrane; carcinoma-associated mucin; polymorphic epithelial mucin; peanut-reactive urinary mucin; tumor associated epithelial mucin; breast carcinoma-associated antigen DF3; tumor-associated epithelial membrane antigen; Medullary cystic kidney disease, autosomal dominant;
- Gene ID
- 4582
- UniProt ID
- P15941
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone C595"
See other products for "MUC1"
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-2049-VHH | Recombinant Anti-human MUC1 VHH Single Domain Antibody | WB, IP, ChiP, Neut, ELISA | Llama VHH |
HPAB-AP504-YC | Recombinant Camel Anti-MUC1 Single Domain Antibody (HPAB-AP504-YC) | FC | Camel VHH |
HPAB-AP505-YC | Recombinant Camel Anti-MUC1 Single Domain Antibody (HPAB-AP505-YC) | ELISA | Camel VHH |
HPAB-0736-YJ-VHH | Camelid Anti-MUC1 Recombinant Single Domain Antibody (HPAB-0736-YJ-VHH) | ELISA | Camelid VHH |
HPAB-0737-YJ-VHH | Camelid Anti-MUC1 Recombinant Single Domain Antibody (HPAB-0737-YJ-VHH) | ELISA | Camelid VHH |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TAB-429MZ. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: Inhib, Cyt
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: WB, ELISA, FC, IP, FuncS, IF, Neut
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: ELISA
Application: FC, IB, Block, Inhib, FuncS, ELISA, FACS, IP, IF
Application: ELISA, IHC, FC, IP, IF, Inhib
Application: ELISA, IHC, WB
Application: ELISA, FuncS, RIA, IP, IF, IHC, IA, Block
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.